Division of Rheumatology, Department of Internal Medicine, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Behçet's Disease Research Center, Cerrahpasa Medical School, Istanbul University-Cerrahpasa, Istanbul, Turkey.
Expert Opin Pharmacother. 2023 Feb;24(2):221-231. doi: 10.1080/14656566.2022.2155047. Epub 2022 Dec 15.
Behçet's syndrome (BS) has a heterogeneous clinical phenotype, and its clinical manifestations may respond differently to drugs commonly used to treat BS. The type, dose, and duration of immunomodulatory, immunosuppressive, and biologic agents should be tailored individually.
We reviewed the literature for articles on BS management that were published until June 2022 and summarized the management options in BS for each type of organ involvement. We aimed to cover all currently available pharmacological agents used in BS, as well as surgical and interventional options, focusing on recent evidence.
The management aims in BS are to preserve function and quality of life and to avoid damage. The choice of treatment modalities depends on the organs that are actively involved, the severity of that involvement, and prognostic factors. A treat-to-attack strategy would help improve long-term outcomes in BS.
贝切特综合征（BS）具有异质性的临床表型，其临床表现可能对常用于治疗 BS 的药物有不同的反应。免疫调节剂、免疫抑制剂和生物制剂的类型、剂量和持续时间应个体化定制。
我们回顾了截至 2022 年 6 月发表的有关 BS 管理的文献，并总结了每种器官受累类型的 BS 管理选择。我们旨在涵盖 BS 中所有现有的药理学药物，以及手术和介入选择，重点关注最新证据。
BS 的治疗目的是保持功能和生活质量，避免损害。治疗方式的选择取决于活跃受累的器官、受累的严重程度和预后因素。攻击治疗策略有助于改善 BS 的长期预后。
